AbCellera Biologics Deferred Revenue | ABCL

Deferred revenue is the amount of money or obligations that a company has received in advance for goods or services that have not yet been delivered or performed. In other words, it is income that has already been received but has not yet been recognized in accounting as revenue because the goods or services have not yet been transferred to the customer.

Features of the metric

Sources of future cash inflows
A high level of deferred revenue indicates that the company has secured future cash flows, which positively affects forecasts of its financial condition and stability.
Assessment of operational stability
Deferred revenue reflects demand for the company’s products or services and its ability to attract customers willing to pay in advance. It is one of the indicators of business stability and its competitive advantages.
Risks and obligations
Although deferred revenue indicates future inflows, it also represents obligations that the company must fulfill. If fulfilling these obligations is delayed or impossible, it can negatively impact reputation and financial results.
Analysis of liquidity and cash flow
Inflows in the form of deferred revenue improve the company’s current liquidity since the funds are already in the accounts. However, investors need to assess the ratio of deferred revenue to fulfilled obligations to understand the actual financial capabilities and risks.
Impact on company valuation
In fundamental analysis, deferred revenue is taken into account for accurate revenue and profit forecasting, especially in industries with long-term contracts or subscriptions (e.g., IT sector, services, manufacturing).

Annual Deferred Revenue AbCellera Biologics

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
13.5 M	13.5 M	19 M	21.6 M	7.54 M	7.53 M	3.24 M	2.33 M	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
21.6 M	2.33 M	11 M

Quarterly Deferred Revenue AbCellera Biologics

2026-Q2	2026-Q1	2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
20.7 M	7.74 M	15.7 M	16.9 M	18.8 M	13.5 M	5.58 M	6.4 M	10.6 M	19 M	17.5 M	8.54 M	11.8 M	21.6 M	6.82 M	4.62 M	9.19 M	7.54 M	6.17 M	10.6 M	11.3 M	6.59 M	6.59 M	6.59 M	6.59 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
21.6 M	4.62 M	11.1 M

Deferred Revenue of other stocks in the Biotechnology industry

Issuer	Deferred Revenue	Price	% 24h	Market Cap	Country
Amryt Pharma plc AMYT	23 M	-	-	$ 621 M	Britain
Acorda Therapeutics ACOR	227 K	-	-24.86 %	$ 820 K	USA
Adaptimmune Therapeutics plc ADAP	12.3 M	-	-15.15 %	$ 60.3 M	Britain
Advaxis ADXS	165 K	-	-9.65 %	$ 45.9 M	USA
Abeona Therapeutics ABEO	296 K	$ 5.42	0.18 %	$ 287 M	USA
iTeos Therapeutics ITOS	4.49 M	-	-	$ 411 M	USA
Galmed Pharmaceuticals Ltd. GLMD	538 K	$ 4.63	21.05 %	$ 20 M	Israel
Lexicon Pharmaceuticals LXRX	3.4 M	$ 2.0	0.3 %	$ 726 M	USA
Alpine Immune Sciences ALPN	16.3 M	-	-	$ 2.17 B	USA
Arbutus Biopharma Corporation ABUS	7.57 M	$ 5.12	0.1 %	$ 981 M	Canada
Ampio Pharmaceuticals AMPE	85.7 K	-	-11.43 %	$ 502 K	USA
NextCure NXTC	4.99 M	$ 7.0	0.55 %	$ 19.9 M	USA
Aridis Pharmaceuticals ARDS	20.2 M	-	17.91 %	$ 11.1 M	USA
Nanobiotix S.A. NBTX	410 K	$ 37.01	0.27 %	$ 1.77 T	France
ACADIA Pharmaceuticals ACAD	2.64 M	$ 27.83	0.32 %	$ 4.69 B	USA
SQZ Biotechnologies Company SQZ	715 K	-	57.95 %	$ 12.8 M	USA
Berkeley Lights BLI	9.09 M	-	-7.31 %	$ 87 M	USA
Achieve Life Sciences ACHV	5.04 M	$ 7.06	0.41 %	$ 308 M	USA
Calithera Biosciences CALA	1.55 M	-	-10.95 %	$ 876 K	USA
CymaBay Therapeutics CBAY	1.69 M	-	-	$ 3.45 B	USA
Codiak BioSciences CDAK	13 M	-	-55.98 %	$ 2.15 M	USA
ChemoCentryx CCXI	11 M	-	-	$ 3.74 B	USA
Avid Bioservices CDMO	39.9 M	-	-	$ 789 M	USA
AC Immune SA ACIU	306 K	$ 2.76	2.6 %	$ 278 M	Schweiz
Cerevel Therapeutics Holdings CERE	356 K	-	-	$ 7.29 B	USA
Aclaris Therapeutics ACRS	3.94 M	$ 5.32	1.27 %	$ 652 M	USA
Adagene ADAG	3.46 M	$ 3.4	2.72 %	$ 201 M	China
ADC Therapeutics SA ADCT	834 K	$ 1.07	0.45 %	$ 136 M	Schweiz
ADMA Biologics ADMA	143 K	$ 9.23	0.16 %	$ 2.2 B	USA
Adaptive Biotechnologies Corporation ADPT	45.2 M	$ 24.2	0.08 %	$ 3.67 B	USA
Agenus AGEN	31 K	$ 6.94	0.73 %	$ 206 M	USA
Agios Pharmaceuticals AGIO	10.9 M	$ 33.6	0.16 %	$ 1.95 B	USA